Hikma launches Icosapent Ethyl Capsules, 0.5g, in the US

London, 21 March 2023 – Hikma Pharmaceuticals PLC (Hikma), the multinational pharmaceutical company, announces it has launched Icosapent Ethyl Capsules in 0.5g dose. Hikma also markets Icosapent Ethyl in 1g capsules and we are pleased to broaden our portfolio with this launch, helping to put better health within reach, every day for millions of people who rely on our medicines.

Press Release Product 21 March 2023

The product, launched in the US, is indicated as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. Hikma’s product is not approved for any other indication for the reference listed drug VASCEPA®[1].

According to IQVIA, US sales of Icosapent Ethyl Capsules, 0.5g, were approximately $22 million in the 12 months ending January 2023.

[1] VASCEPA® is a registered trademark of Amarin Pharmaceuticals Ireland Limited

This product has been approved for marketing in the United States by the US FDA.  This product approval does not confer the right on Hikma, or any other party, to market this product outside the United States.


Important Safety Information for Icosapent Ethyl Capsules, 0.5g:


Icosapent ethyl is contraindicated in patients with known hypersensitivity (eg, anaphylactic reaction) to icosapent ethyl or any of its components.


  • Atrial Fibrillation/Flutter
    In a double-blind, placebo-controlled trial, icosapent ethyl was associated with an increased risk (3% vs 2%) of atrial fibrillation or atrial flutter requiring hospitalization. The incidence of atrial fibrillation was greater in patients with a previous history of atrial fibrillation or atrial flutter.

  • Potential for Allergic Reactions in Patients With Fish Allergy
    It is not known whether patients with allergies to fish and/or shellfish are at increased risk of an allergic reaction to icosapent ethyl. Inform patients with known hypersensitivity to fish and/or shellfish about the potential for allergic reactions and advise them to discontinue use and seek medical attention if any reactions occur.

  • Bleeding
    In a double-blind, placebo-controlled trial, icosapent ethyl was associated with an increased risk (12% vs 10%) of bleeding. The incidence of bleeding was greater in patients receiving concomitant antithrombotic medications, such as aspirin, clopidogrel or warfarin.


The following important adverse reactions are described in the full Prescribing Information for Icosapent Ethyl capsules:

  • Atrial Fibrillation or Atrial Flutter
  • Potential for Allergic Reactions in Patients With Fish Allergy
  • Bleeding

Common adverse reactions (incidence ≥3% on icosapent ethyl and ≥1% more frequent than placebo) included musculoskeletal pain, peripheral edema, constipation, gout and atrial fibrillation.

In hypertriglyceridemia trials, adverse reactions reported with icosapent ethyl (incidence ≥1% more frequent than placebo) included arthralgia and oropharyngeal pain.


  • Increased Bleeding Risk With Anticoagulants and Antiplatelet Agents
    Monitor patients receiving icosapent ethyl and concomitant anticoagulants and/or antiplatelet agents for bleeding.


  • Lactation
    Lactating women receiving oral omega-3 fatty acids for supplementation have resulted in higher levels of omega-3 fatty acids in human milk. There are no data on the effects of omega-3 fatty acid ethyl esters on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered, along with the mother’s clinical need for icosapent ethyl and any potential adverse effects on the breastfed child from icosapent ethyl or from the underlying maternal condition.
  • Pediatric Use
    Safety and effectiveness in pediatric patients have not been established.
  • Hepatic Impairment
    In patients with hepatic impairment, alanine aminotransferase and aspartate aminotransferase levels should be monitored periodically during therapy with icosapent ethyl.


Icosapent ethyl is indicated:

  • as an adjunct to diet to reduce triglyceride levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia.

Limitations of use

The effect of icosapent ethyl on the risk for pancreatitis in patients with severe hypertriglyceridemia has not been determined.


For more information, please see the full Prescribing Information and Medication Guide.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit https://www.fda.gov/medwatch or call 1-800-FDA-1088.

Manufactured by: Catalent Pharma Solutions, LLC., St. Petersburg, Florida 33716

Distributed by: Hikma Pharmaceuticals USA Inc., Eatontown, NJ 07724

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.